Berberine chloride (NSC 646666)

目录号:S2271 别名: Natural Yellow 18 chloride 中文名称:盐酸小檗碱,黄连素

仅限科研使用

Berberine chloride (NSC 646666, Natural Yellow 18)是异喹啉类生物碱的季铵盐。Berberine chloride 可激活 caspase 3caspase 8,分裂 poly ADP-ribose polymerase (PARP) 和释放 cytochrome c。Berberine chloride 可降低 c-IAP1Bcl-2Bcl-XL 的表达。Berberine chloride 可通过 JNKp38 MAPK 的持续磷酸化以及产生 ROS 来诱导凋亡。Berberine chloride 是一个 topoisomerase III 的双效抑制剂。Berberine chloride 也是一个潜在的自噬调节剂。

Berberine chloride (NSC 646666) Chemical Structure

CAS: 633-65-8

规格 价格 库存 购买数量
RMB 571.33 现货
RMB 1718.64 现货
RMB 3866.12 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Berberine chloride (NSC 646666)发表文献7篇:

产品安全说明书

Anti-infection抑制剂选择性比较

生物活性

产品描述 Berberine chloride (NSC 646666, Natural Yellow 18)是异喹啉类生物碱的季铵盐。Berberine chloride 可激活 caspase 3caspase 8,分裂 poly ADP-ribose polymerase (PARP) 和释放 cytochrome c。Berberine chloride 可降低 c-IAP1Bcl-2Bcl-XL 的表达。Berberine chloride 可通过 JNKp38 MAPK 的持续磷酸化以及产生 ROS 来诱导凋亡。Berberine chloride 是一个 topoisomerase III 的双效抑制剂。Berberine chloride 也是一个潜在的自噬调节剂。
靶点
Caspase-3 [1] Caspase-8 [1] PARP [1] cytochrome c [1] cIAP1 [1] 点击更多
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MRC5 cells M2LPcGZ2dmO2aX;uJIF{e2G7 NIrtb4hCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS02YIHnuJG1TSzViY3XscJMh[nlicHzhdZVmKHKnZIXjeIlwdiCjc4PhfUwhUUN3ME2wMlY5KM7:TR?= MYWxO|I{QTV7NB?=
MRC5 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 MXOxNEDPxE1? MnPiOVQhcHK| M3ftZ2lvcGmkaYTpc44hd2ZiSFPNWkBxem:uaX\ldoF1cW:wIHnuJG1TSzViY3XscJMh[W[2ZYKgOVQhcHK|IIDvd5QucW6oZXP0bY9vKGG2IEGwJJVOKGK7IIDsZZF2\SCjc4PhfS=> M1;W[FE4OjN7NUm0
MRC5 cells M3zDdXBzd2yrZnXyZZRqd25iYYPzZZk> NH3GNWwyOCEQvF2= NUfx[5c3OjRiaB?= NX;WXmFlUW6qaXLpeIlwdiCxZjDIR21XKHC{b3zp[oVz[XSrb36gbY4hVVKFNTDj[YxteyCjZoTldkAzPCCqcoOgdI9{fC2rbn\lZ5Rqd25iYYSgNVAhfU1iYomgdIxieXWnIHHzd4F6 MU[xO|I{QTV7NB?=
Bel7402 cells NGK3Z4VHfW6ldHnvckBie3OjeR?= M2jtVFEzKGh? M3;ZVWlv\HWldHnvckBw\iCORFzSJJBzd3SnaX6gbY4hcHWvYX6gRoVtPzRyMjDj[YxteyCjZoTldkAyOiCqcoOgZpkhWlRvUFPSJIF{e2G7IILlcIF1cX[nIITvJINwdnS{b3y= NGm2XosyQTB7MEe2Oy=>
HepG2 cells NGXRb5JHfW6ldHnvckBie3OjeR?= MVmxNEB2\y:vTB?= NHGzO|kyOiCq MUjJcoR2[3Srb36gc4YhVESOUjDwdo91\WmwIHX4dJJme3Orb36gbY4hcHWvYX6gTIVxTzJiY3XscJMh[XRiMUCgeYcwdUxiYX\0[ZIhOTJiaILzJIJ6KG[ub4egZ5l1d22ndIL5 MXixPVA6ODd4Nx?=
KB cells MnqyR5l1d3SxeHnjbZR6KGG|c3H5 NGTTVHU4OiCq Ml3pR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2Ih[2WubIOgZYZ1\XJiN{KgbJJ{NCCLQ{WwQVcvOzJizszN MorMNVEyPDFzMEW=
HL60 cells NUTuN493SXCxcITvd4l{KGG|c3H5 M1joRVQ5KGi{cx?= Ml:yTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDR6IHjyd{B2e2mwZzDhco5mgGmwIG[tdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDifUBHSUOVIHHuZYx6e2m| M3e5SlIxOjJ5MUS0
A549 cells NV\Gfm5qS3m2b4TvfIlkcXS7IHHzd4F6 M1jUfWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[nliU2LCJIF{e2G7LDDJR|UxRTZwMkeg{txO MmXtNlA2QTR6NEi=
SKOV3 cells NWrHPYkxS3m2b4TvfIlkcXS7IHHzd4F6 NEjI[JFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUU0:YMzDj[YxteyCkeTDTVmIh[XO|YYmsJGlEPTB;MU[uOFQh|ryP MX2yNFU6PDh2OB?=
SK-MEL-2 cells MUHDfZRwfG:6aXPpeJkh[XO|YYm= NWnpZ4J1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTVXMMVIh[2WubIOgZpkhW1KEIHHzd4F6NCCLQ{WwQVE{Njd4IN88US=> NY[0bVNGOjB3OUS4OFg>
HCT15 cells MWfDfZRwfG:6aXPpeJkh[XO|YYm= MXrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyPSClZXzsd{BjgSCVUlKgZZN{[XluIFnDOVA:OTZwNUmg{txO NEHEZo0zODV7NEi0PC=>
CEM cells M{jhVWN6fG:2b4jpZ4l1gSCjc4PhfS=> NYLLcmZtPDhiaILz MmLNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIV5eHKnc4Ppcoch\3KnZX6g[ox2d3Knc3PlcpQheHKxdHXpckBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5MEBESzVyPUKuNFkh|ryP M{LDVVIyOjl3OEmx
human CEM cells MWTGeY5kfGmxbjDhd5NigQ>? NWTzNXlkPyCmYYnz M1TUdGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JFAvODViTV;JJGh2dWGwIHntcZVvd2SnZnnjbYVv[3lidnnyeZMhOSCQTESuN{Bqdm[nY4Tl[EBqdiCqdX3hckBETU1iY3XscJMh\XiycnXzd4lv\yCpcnXlckBndHWxcnXzZ4VvfCCycn;0[YlvKGG|c3Xzd4VlKGG|IICyOEBidnSrZ3XuJJBzd2S3Y4Tpc44hdWWjc4Xy[YQhPyCmYYnzJJBwe3RiaX7m[YN1cW:wIHL5JGVNUVODLDDFR|UxRTBwMUOg{txO MYOyNVI6PTh7MR?=
SKN cells M3jiXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXi3NkBp MYTHdo94fGhiaX7obYJqfGmxbjDh[4FqdnO2IHj1cYFvKFONTjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCJSUWwQVE2Njh6IN88US=> NFXvWZMzOTRyMUGxOC=>
RKN cells NUPNfZBGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXzuWFVZPDhiaILz MlvyS5Jwf3SqIHnubIljcXSrb36gZYdicW6|dDDoeY1idiCUS16gZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF01QS54IN88US=> M1zmb|IyPDBzMUG0
G402 cells NYrKPGZ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXq2ZlB[PDhiaILz MUHHdo94fGhiaX7obYJqfGmxbjDh[4FqdnO2IHj1cYFvKEd2MEKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0yOS56NzFOwG0> NVTnOpVOOjF2MEGxNVQ>
A10 cells M3u5bGZ2dmO2aX;uJIF{e2G7 M4fCbVMxKM7:TR?= NETZTWMzPCCqcoO= MmXVSI94dnKnZ4XsZZRqd25ib3[gV4NlOiCvUl7BJIV5eHKnc4Ppc44hcW5icnH0JGEyOCClZXzsd{BifCB|MDD1UUBi\nSncjCyOEBpenNiYomgdZVidnSrdHH0bZZmKFKWLWDDVkBidmGueYPpdy=> MkXhNlE1ODFzMUS=
A10 cells MoXDSpVv[3Srb36gZZN{[Xl? MWezNEDPxE1? NYDleYFLOjRiaILz MVHEc5dvKHKnZ4XsZZRqd25ib3[gVJJqdTJibWLORUBmgHC{ZYPzbY9vKGmwIILheEBCOTBiY3XscJMh[XRiM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JJF2[W62aYTheIl3\SCUVD3QR3Ih[W6jbInzbZM> M3ThVlIyPDBzMUG0
A10 cells NXznPJJRTnWwY4Tpc44h[XO|YYm= NVXPepNsOzBizszN M4\BRVI1KGi{cx?= M2fCXWRwf26{ZXf1cIF1cW:wIH;mJGlueGtibWLORUBmgHC{ZYPzbY9vKGmwIILheEBCOTBiY3XscJMh[XRiM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JJF2[W62aYTheIl3\SCUVD3QR3Ih[W6jbInzbZM> MlnKNlE1ODFzMUS=
HepG2-A16-CD81 cells MWfGeY5kfGmxbjDhd5NigQ>? NHj4dJEyOCEQvF2= NVvndm9mVk:YQWLUTXM7KEGwdHntZYxiemmjbDDsbZZmeiC|dHHn[UBi[3Srdnn0fUBu\WG|dYLl[EBieyCjIHfy[YF1\XJidHjhckA2OCVicnXkeYN1cW:wIHnuJHBt[XOvb3TpeY0hgW:nbHnpJJNkcGm8b370JIFz\WFiaX6gTIVxTzJvQUG2MWNFQDFiY3XscJMh[XRiMUD1UUBkd22yb4Xu[EBkd26lZX70doF1cW:wLDDk[ZRmem2rbnXkJIJ6KGmvbYXuc{1ndHWxcnXzZ4Vv[2Vw MX6yNlA6PjFyMR?=
HepG2-A16-CD81 cells M3jC[mZ2dmO2aX;uJIF{e2G7 NIDxNmoyOCEQvF2= NETYPYRPV1[DUmTJV|ohSW62aX3hcIFzcWGuIHzpeoVzKHO2YXflJIFkfGm4aYT5JI1m[XO3cnXkJIF{KHKnZIXjeIlwdiCrbjDQcIF{dW:maYXtJJlw\WyraTDzZ4hqgm:wdDDhdoViKGmwIFjldGczNUFzNj3DSFgyKGOnbHzzJIJ6KGmvbYXuc{1ndHWxcnXzZ4Vv[2VuIHHu[EBu\WSrYX6gd4NpcXqxboSgd4l7\SCjdDCxNJVOKGOxbYDveY5lKGOxbnPlcpRz[XSrb36sJGlEPTB;MD61OFgh|ryP NWrxbHZMOjJyOU[xNFE>
HepG2 cells M3\idmZ2dmO2aX;uJIF{e2G7 M2nD[FExKM7:TR?= MkPrOEBp M1TpWWlv[3KnYYPlJIlvKEGPUFvhcJBp[SCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m|IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s NHS0ZpozOzB3OEGwOy=>
HepG2 cells NXHPclJDTnWwY4Tpc44h[XO|YYm= NWfBOFBsOTBizszN M1W5SFQhcA>? NXfkWZVDUW6lcnXhd4UhcW5idH;0ZYwhSU2SS3HsdIhiKGyndnXsJIlvKGi3bXHuJGhmeEd{IHPlcIx{KGG2IEGwJJVOKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyC{ZXzheIl3\SC2bzD1cpRz\WG2ZXSgZ49vfHKxbB?= M{HwS|I{ODV6MUC3
HepG2 cells MnL6SpVv[3Srb36gZZN{[Xl? M4LoTVIxKM7:TR?= M2e1V|I1KGi{cx?= MmHtTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bud3KyaH;sc4dq[2GuIHPoZY5o\XNiYYSgNlAhfU1iYX\0[ZIhOjRiaILzJJV{cW6pIFjv[YNpe3RiM{OyOVghe3SjaX7pcoch[nliZnz1c5Jme2OnbnPlJI1q[3Kxc3PvdIlkKGGwYXz5d4l{ M2\ONFI{OTh{MEi4
HT-29 cells MWnDfZRwfG:6aXPpeJkh[XO|YYm= MnPGOFghcHK| Mm\hR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME24MlQ2KM7:TR?= NG\wRWgzOzF6MkC4PC=>
HepG2 cells Ml\lR5l1d3SxeHnjbZR6KGG|c3H5 NH3kOVIzPCCqcoO= M4qxRmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVEvOjJizszN NF3We|UzOzF6MkC4PC=>
HepG2 cells NFPnW|REgXSxdH;4bYNqfHliYYPzZZk> NV7v[FJ3PDhiaILz Mn7MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME24MlMzKM7:TR?= NEjrVYEzOzF6MkC4PC=>

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+ddH2O

3mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 371.81
化学式

C20H18NO4.Cl

CAS号 633-65-8
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05463003 Not yet recruiting Dietary Supplement: Berberine Pharmacokinetic Study in Healthy Volunteers University Medicine Greifswald July 2022 Not Applicable
NCT03281096 Completed Drug: Berberine hydrochloride|Drug: Placebo Colorectal Adenomas Xijing Hospital of Digestive Diseases August 29 2017 Phase 2|Phase 3

(data from https://clinicaltrials.gov, updated on 2022-08-01)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们